Up to 30% of individuals will suffer in their lifetime from anxiety, obsessive-compulsive, and posttraumatic stress disorders that are characterized by deficits in fear responses and extinction.
Although cognitive behavioral therapy (CBT) and serotonin reuptake inhibitors are efficacious in symptom alleviation, a substantial number of patients do not respond to these first-line treatments.
Thus, the race toward identifying drugs that augment the effects of CBT has intensified over the last two decades. The current frontrunner in this race is D-cycloserine (DCS), a partial N-methyl-D-aspartate receptor agonist that has been shown in animal studies to facilitate fear extinction…..
More from News: